Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of bevacizumab added to neoadjuvant chemotherapy in breast cancer
2009-014773-40Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in breast cancer and inflammatory breast cancer (IBC) (2 arms), sponsored by Institut Paoli-Calmettes. Primary endpoint: Change in ALDH1-positive cell percentage. Started Oct 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2009-014773-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014773-40.